Osteopontin is a tumor autoantigen in prostate cancer patients

Oncology Letters

Volumn 2, Issue 1, 2011, Pages 109-114

  Tilli, Tatiana M ^a   Silva, Eloïsio A ^b   Matos, Lïvia C ^c   Faget, Douglas V ^a   Dias, Bianca F P ^a   Vasconcelos, Juliana S P ^b   Yokosaki, Yasuyuki ^e   Gimba, Etel R P ^a,d  

^a Instituto Nacional de Câncer   (Japan)

^b Universidade do Estado do Rio de Janeiro   (Japan)

^c UNIVERSITY OF BRASILIA   (Brazil)

^d FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^e HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Autoantibodies; Osteopontin; Prostate cancer; Tumor antigen

Indexed keywords

AUTOANTIGEN; OSTEOPONTIN; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT OSTEOPONTIN; RECOMBINANT PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOBLOTTING; IMMUNOREACTIVITY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR BIOPSY;

EID: 78751541867     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2010.211     Document Type: Article

References (31)

1. Miller J and Tarter TH: Update on the use of dutasteride in the management of benign prostatic hypertrophy. Clin Interv Aging2: 99-104, 2007.
2. Taylor BS, Pal M, Yu J, et al: Humoral response profiling reveals pathways to prostate cancer progression. Mol Cell Proteomics 7: 600-611, 2008.
3. Lu H, Goodell Vand Disis ML: Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 7: 1388-1394, 2008.
4. Cho-Chung YS: Autoantibody biomarkers in the detection of cancer. Biochim Biophys Acta 1762: 587-591, 2006.
5. Lubin R, Schlichtholz B, Teillaud JL, et al: p53 antibodies in patients with various types of cancer: assay, identification and characterization. Clin Cancer Res 1: 1463-1469, 1995.
6. Storr SJ, Chakrabarti J, Barnes A, et al: Use of autoantibodies in breast cancer screening and diagnosis. Expert Rev Anticancer Ther 6: 1215-1223, 2006.
7. Bachelot T, Ratel D, Menetrier-Caux C, et al: Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer 94: 1066-1070, 2006.
8. Vural B, Chen LC, Saip P, et al: Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer 103: 2575-2583, 2005.
9. Jacobs JP, Pettit AR, Shinohara ML, et al: Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody-mediated arthritis. Arthritis Rheum 50: 2685-2694, 2004.
10. Stromnes IM and Goverman JM: Osteopontin-induced survival of T cells. Nat Immunol 8: 19-20, 2007.
11. Shevde LA, Das S, Clark DW, et al: Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 10: 71-81, 2010.
12. Fedarko NS, Jain A, Karadag A, et al: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7: 4060-4066, 2001.
13. Hotte SJ, Winquist EW, Stitt L, et al: Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95: 506-512, 2002.
14. Wai PY and Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27: 103-118, 2008.
15. Forootan SS, Foster CS, Aachi VR, et al: Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer118: 2255-2261, 2006.
16. Sakata M, Tsuruha JI, Masuko-Hongo K, et al: Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 28: 1492-1495, 2001.
17. Yokosaki Y, Matsuura N, Sasaki T, et al: The integrin alpha(9) beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 274: 36328-36334, 1999.
18. Chung CT, Niemela SL and Miller RH: One-step preparation of competent Escherichia coli: trasformation and storage of bacterial cells in the same solution. Proc Natl Acad Sci USA 86: 2172-2175, 1989.
19. Sardana G, Dowell B and Diamandis EP: Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem54: 1951-1960, 2008.
20. Bensalah K, Lotan Y, Karam JA, et al: New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 11: 112-120, 2008.
21. Du H, Masuko-Hongo K, Nakamura H, et al: The prevalence of autoantibodies against cartilage intermediate layer protein, YKL-39, osteopontin, and cyclic citrullinated peptide in patients with early-stage knee osteoarthritis: evidence of a variety of autoimmune processes. Rheumatol Int 26: 35-41, 2005.
22. Watanabe M, Uchida K, Nakagaki K, et al: Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett581: 2017-2021, 2007.
23. Tomer Y, Sherer Y and Shoenfeld Y: Autoantibodies, autoimmunity and cancer. Oncol Rep 5: 753-761, 1998.
24. Adler AJ: Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones. Curr Cancer Drug Targets 7: 3-14, 2007.
25. Casiano C.A., Mediavilla-Varela M. and Tan E.M.: Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics 5: 1745-1759, 2006.
26. Thalmann GN, Sikes RA, Devoll RE, et al: Osteopontin: possible role in prostate cancer progression. Cancer Res 5: 2271-2277, 1999.
27. Bradley SV, Oravecz-Wilson KI, Bougeard G, et al: Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res 65: 4126-4133, 2005.
28. Pontes ER, Matos LC, da Silva EA, et al: Auto-antibodies in prostate cancer: humoral immune response to antigenic determinants coded by the differentially expressed transcripts FLJ23438 and VAMP3. Prostate 66: 1463-1473, 2006.
29. Shi F, Zhang J, Liu D, et al: Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 63: 252-258, 2005.
30. Sreekumar A, Laxman B, Rhodes DR, et al: Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 96: 834-843, 2004.
31. Leman ES and Getzenberg RH: Biomarkers for prostate cancer. J Cell Biochem 108: 3-9, 2009.